We've found
					52,953 Cancer				
					clinical trials				
				
			
		
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Breast Cancer Clinical Trial
	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
						
				
			
We've found
					52,953 Cancer
				
					clinical trials
				
				
				
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Breast Cancer Clinical Trial
	
Updated: 12/31/1969
  
  
  Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
		Status: Enrolling,
							Phase
													 III			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials